GlassScriptPhysician profile
Michael Yman Dejesus
NPI 1417903311
$36,867.86
in general payments reported to CMS, 2019-2025
9 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $7,173 · 2021: $6,118 · 2022: $4,420 · 2023: $298 · 2024: $228 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $35,662.84 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Janssen Biotech, INC. | $860.55 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Pfizer INC. | $149.44 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $100.64 | 2024-2025 | Voquezna |
| Medtronic, INC. | $28.37 | 2025 | Interstim |
| Regeneron Healthcare Solutions, INC. | $20.92 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $16.10 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.91 | 2023 | Xifaxan |
| Fresenius Kabi USA, LLC | $14.09 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dejesus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.